ReviewCost effectiveness and resource allocation : C/E2024
An overview of the perspectives used in health economic evaluations.
Review in Cost effectiveness and resource allocation : C/E, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Consideration of intersectoral costs and benefits in health economic evaluations of pneumococcal conjugate vaccines: a systematic review.International journal of technology assessment in health care · 2026Pooled it
- Adverse Drug Reaction Costs and Study Quality in Africa: A Systematic Review of Cost-of-Illness Studies.PharmacoEconomics - open · 2026Pooled it
- Costs of resolving a ureteral or kidney stone episode worldwide: a systematic review.International urology and nephrology · 2026Pooled it
- Economic evaluation of sodium-glucose transporter 2 inhibitors compared with glucagon-like peptide 1 receptor agonist for the treatment of type 2 diabetes: a systematic review.European journal of clinical pharmacology · 2026Pooled it
- GLP-1 receptor agonists for treating obesity without diabetes: A systematic review and meta-analysis of economic evaluations.Diabetes, obesity & metabolism · 2026Pooled it
- Cost and economic burden associated with caring for children with Down syndrome: a systematic review.BMJ paediatrics open · 2025Pooled it
- Costs of mental health care resource use in people with obesity: A systematic review.PloS one · 2025Pooled it
- Trial
- Cost-utility and cost-effectiveness of SELFIE, a transdiagnostic ecological momentary intervention for improving self-esteem in youth aged 12-26 years exposed to childhood adversity: Findings from a multicenter randomized controlled trial.Psychological medicine · 2026Trial
- Predicting effect and evaluating cost-effectiveness of a family intervention after acquired brain or spinal cord injury: a randomized controlled trial.Journal of rehabilitation medicine · 2026Trial
- Trial
- Cost-effectiveness analysis of emicizumab use in hospitalized older individuals with acquired hemophilia A.Blood vessels, thrombosis & hemostasis · 2026Article
- The Challenge of Unit Cost Harmonisation: A French National Reference Unit Cost for Healthcare Services (the MOVIE Project).Applied health economics and health policy · 2026Article
- Healthcare utilization and 30-day in-hospital costs following brain tumor surgery: A single-center, retrospective cohort study.Neuro-oncology practice · 2026Article
- Economic Evaluations of Physical Exercise at Work: A Scoping Review.Journal of occupational rehabilitation · 2026Review
- Costs of Comorbidities and Complications Associated with Type 2 Diabetes: A Retrospective, Cohort Study.Advances in therapy · 2026Article
- A Multidisciplinary Integrated Care Program for Complex Chronic Patients: A Real-World Evaluation of Healthcare Utilization and Provider Costs.Healthcare (Basel, Switzerland) · 2026Article
- Uncertainty in Economic Evaluation: A Pragmatic Guide for Health Technology Assessment (HTA) Agencies in Resource-Constrained Settings.PharmacoEconomics · 2026Review
- Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Methamphetamine-Associated Heart Failure in the United States.Journal of the American Heart Association · 2026Article
- The true cost of red cell transfusion for patients with myelodysplastic syndromes: A time-driven activity-based costing study.British journal of haematology · 2026Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The term 'perspective' in the context of economic evaluations and costing studies in healthcare refers to the viewpoint that an analyst has adopted to define the types of costs and outcomes to consider in their studies. However, there are currently notable variations in terms of methodological recommendations, definitions, and applications of different perspectives, depending on the objective or intended user of the study. This can make it a complex area for stakeholders when interpreting these studies. Consequently, there is a need for a comprehensive overview regarding the different types of perspectives employed in such analyses, along with the corresponding implications of their use. This is particularly important, in the context of low-and-middle-income countries (LMICs), where practical guidelines may be less well-established and infrastructure for conducting economic evaluations may be more limited. This article addresses this gap by summarising the main types of perspectives commonly found in the literature to a broad audience (namely the patient, payer, health care providers, healthcare sector, health system, and societal perspectives), providing their most established definitions and outlining the corresponding implications of their uses in health economic studies, with examples particularly from LMIC settings. We then discuss important considerations when selecting the perspective and present key arguments to consider when deciding whether the societal perspective should be used. We conclude that there is no one-size-fits-all answer to what perspective should be used and the perspective chosen will be influenced by the context, policymakers'/stakeholders' viewpoints, resource/data availability, and intended use of the analysis. Moving forward, considering the ongoing issues regarding the variation in terminology and practice in this area, we urge that more standardised definitions of the different perspectives and the boundaries between them are further developed to support future studies and guidelines, as well as to improve the interpretation and comparison of health economic evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.